Amicus Therapeutics, Inc. To Present At The BioCentury/BioCentury Publications Inc. 'Future Leaders In The Biotech Industry' Conference
CRANBURY, N.J., March 28 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has been selected to present at the 13th "Future Leaders in the Biotech Industry" conference sponsored by BioCentury and Thomson Financial. John Crowley, president and CEO, will provide an overview of the company, the technology, and the status of current development programs. The presentation will take place at 9:30 a.m. on Thursday, March 30, at the Millennium Broadway Hotel & Conference Center in New York.
Amicus develops pharmacological chaperones, orally-delivered small molecules that selectively bind to misfolded proteins to restore shape, proper trafficking and biological function. Amicus' lead compound, Amigal(TM) (migalastat hydrochloride), is currently being studied in Phase II clinical trials for Fabry disease. The company expects to initiate clinical studies of a second product, AT2101 for the treatment of Gaucher disease, in the first half of this year. Amicus recently announced that AT2101 has received orphan drug designation from the U.S. Food and Drug Administration.
In addition to these two lead programs, the company has a growing pipeline of other products for a range of genetic diseases.
Additional information about Amicus can be found at http://www.amicustherapeutics.com
CONTACTS: Corporate: Media: Matthew Patterson Stephen Gendel Amicus Therapeutics GendeLLindheim BioCom Partners (609) 662-2000 (212) 918-4650Amicus Therapeutics
CONTACT: Corporate: Matthew Patterson of Amicus Therapeutics,+1-609-662-2000; Media: Stephen Gendel of GendeLLindheim BioCom Partnersfor Amicus Therapeutics, +1-212-918-4650
Web site: http://www.amicustherapeutics.com/